NEW YORK, Feb. 23 /PRNewswire/ -- The growing impact that China is having on the global pharmaceutical marketplace is currently being felt by the industry on a wide scale in areas such as outsourcing, clinical trials, manufacturing and more recently, drug discovery and development. In an effort to reduce costs, shorten time-to-market, and find new avenues for growth, the pharmaceutical and biotech industry is increasingly looking to China. All of this, coupled with China's fast-growing economy, has made China the world's fastest growing pharmaceutical market. But what should the industry realistically expect from China in short and long term?

"Impact China II: Pharmaceutical R&D Global Summit," an event organized by the Strategic Research Institute, will separate the "hype vs. reality" surrounding the Chinese market by providing an unprecedented look into the current state of the industry. Scheduled to take place on May 21-24, 2006 in Beijing, China, this groundbreaking series will lend a platform for hundreds of scientific and business leaders in the pharmaceutical industry to discuss the opportunities and challenges ahead in the rapidly developing Chinese market.

Over 75 speakers will participate in presentations, panel discussions and workshops covering:

    * A Comparison of China vs. India, Japan, Asia-Pacific     * Intellectual Property & Patent Protection/Enforcement     * Venture Capital Investment, Technology Valuation/Transfer, East/West       M&A's     * The Emerging Drug Discovery Landscape in China     * Outsourcing Preclinical & Clinical R&D to China     * Manufacturing, APIs and Generics in China     * Regulatory Insights in Clinical Trials, GMPs and Drugs/Biologics     * Business Practices, Commercialization and Marketing Strategies in the       Chinese Market     * East/West Partnerships, Licensing, and Business Development Strategies